搜索公司,投資者……

預測你的未來投資

腋資本公司的標誌
風險資本
axilcapital.com

投資

14

投資退出

3

基金

1

對腋資本

腋資本是一個基於風險投資公司在東京,日本,專門從事生物醫學與醫療技術投資,強調支持早期風險投資的發展。

總部的位置

日本生命科學大樓2,504房間3-11-5 Nihonbashi-Honcho,東京都中央區

東京,103 - 0023,

日本

+ 81-3-3527-2212

想告知投資者類似腋資本關於你的公司嗎?

提交你的分析師簡報在投資者麵前,CB Insights的平台上的客戶和合作夥伴。188bet游戏

最新的腋資本新聞

Suono生物有限公司宣布超額認購資金輪腋資本和瑞穗證券投資本金

2021年7月14日

Suono生物有限公司宣布超額認購資金輪腋資本和瑞穗證券首席投資的福克斯,質量。,July 13, 2021-- Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced it has raised an $8.5 million Series A financing led by Axil Capital and Mizuho Securities Principal Investment, with participation by Taiwania Capital and other investors. Suono Bio will utilize the funds to advance its lead programs in inflammatory bowel disease as well as expansion of its pipeline. Suono Bio’s platform technology enables the rapid, targeted delivery of drugs, including gene therapies, for the first time, enabling the use of the right drug in the right patient. Suono Bio leverages technology developed in the laboratory of Institute Professor Robert Langer at the Massachusetts Institute of Technology (MIT) to facilitate rapid, local administration of therapeutics to treat serious diseases. The company was founded by Professor Langer, Professor Giovanni Traverso, from the Department of Mechanical Engineering at MIT and a gastroenterologist and biomedical engineer at Brigham and Women’s Hospital, Harvard Medical School, and Dr. Carl Schoellhammer. Publications on the technology have appeared in Nature, Gastroenterology, and Science Translational Medicine, and the company has previously announced strategic investments from FUJIFILM Corporation and NGK Spark Plug Co., LTD. “Suono Bio’s technology is poised to accelerate novel therapeutics to the clinic by finally overcoming the challenges with delivering drugs like DNA or RNA,” said Frederick Shane, Managing Partner of Axil, who joined the Board of Directors. “Their technology spans beyond a single product or asset to a whole new platform of products to treat debilitating diseases and we are thrilled to lead this round,” he added. “We are thrilled to have marquee investors involved with Suono Bio and speaks to the rapid pace with which the team has taken a conceptual technology from Prof. Langer’s lab and operationalized it to address pressing health issues,” said Scott Kellogg, CEO. Proceeds from the Series A financing will allow completion of the development of the company’s first product for treating ulcerative colitis, readying it for human trials, and further the development of the overall technology platform. “The ability to deliver macromolecules, including DNA and RNA based medicines outside of the liver and in a formulation-independent approach could be applied to many diseases and benefit a tremendous number of patients,” said Professor Robert Langer, co-founder and Board Member. “We are excited to be able to advance the development of an approach which has the capacity to rapidly and effectively deliver a broad array of therapeutics from small molecules to nucleic acids,” added Professor Giovanni Traverso, co-founder and Board Member. ABOUT SUONO BIO Suono Bio is developing therapeutic products for inflammatory-mediated diseases leveraging their ultra-rapid and formulation independent delivery technology. Suono Bio’s platform was developed at The Massachusetts Institute of Technology in Professor Robert Langer’s laboratory and enables rapid, localized delivery of small molecules, biologics, and nucleic acids and gene therapies without the need for encapsulation of the therapeutic. For more information, please visit www.suonobio.com. ABOUT AXIL CAPITAL Axil Capital Partners is a Tokyo based venture capital firm specializing in biomedical & healthcare technology investments with an emphasis on supporting the growth of early-stage ventures. The firm invests in a wide range of companies in the life sciences space, with a particular focus on cross-disciplinary technologies that can transform the future of healthcare. For more information, please visit https://www.axilcapital.com/. Contact:

腋資本投資

14投資

腋資本了14投資他們最新的投資Cellusion作為他們的一部分C係列2023年6月6日

CBI的標誌

腋資本投資活動

投資表

日期

公司

新的嗎?

共同投資者

來源

6/7/2023

C係列

Cellusion

20.3美元

是的

3

6/11/2021

一個係列

Aibios

7.02美元

沒有

2

3/25/2021

一個係列

Suono生物

8.5美元

是的

3

3/3/2021

B係列

訂閱看到更多

99美元

訂閱看到更多

10

11/10/2020

B係列

訂閱看到更多

99美元

訂閱看到更多

10

日期

6/7/2023

6/11/2021

3/25/2021

3/3/2021

11/10/2020

C係列

一個係列

一個係列

B係列

B係列

公司

Cellusion

Aibios

Suono生物

訂閱看到更多

訂閱看到更多

20.3美元

7.02美元

8.5美元

99美元

99美元

新的嗎?

是的

沒有

是的

訂閱看到更多

訂閱看到更多

共同投資者

來源

3

2

3

10

10

腋資本投資退出

3組合退出

腋資本3投資組合出口。他們最新的投資退出珀爾修斯蛋白質組學 2021年6月22日

日期

退出

公司

估值
提交的估值公司,采自國家申請或者新聞,由VentureSource的提供,或基於比較數據的估值模型。

收購者

來源

6/22/2021

首次公開募股

99美元

公共

3

10/2/2020

首次公開募股

訂閱看到更多

99美元

訂閱看到更多

10

10/3/2019

首次公開募股

訂閱看到更多

99美元

訂閱看到更多

10

日期

6/22/2021

10/2/2020

10/3/2019

退出

首次公開募股

首次公開募股

首次公開募股

公司

訂閱看到更多

訂閱看到更多

估值

99美元

99美元

99美元

收購者

公共

訂閱看到更多

訂閱看到更多

來源

3

10

10

腋資本基金的曆史

1基金曆史

腋資本1 基金,包括腋生命科學和醫療基金

截止日期

基金

基金類型

狀態

來源

腋生命科學和醫療基金

1

截止日期

基金

腋生命科學和醫療基金

基金類型

狀態

來源

1

腋資本團隊

2團隊成員

腋資本2 團隊成員,包括當前的管理合夥人,弗雷德·謝恩

的名字

工作經曆

標題

狀態

弗雷德肖恩

管理合夥人

當前的

訂閱看到更多

訂閱看到更多

訂閱看到更多

的名字

弗雷德肖恩

訂閱看到更多

工作經曆

標題

管理合夥人

訂閱看到更多

狀態

當前的

訂閱看到更多

發現正確的解決方案為您的團隊

CB見解188bet游戏科技市場情報平台分析數百萬數據點在供應商、產品、合作關係,專利來幫助您的團隊發現他們的下一個技術解決方案。

請求一個演示

CBI的網站通常使用一些餅幹,使更好的相互作用我們的網站和服務。使用這些餅幹,這可能是存儲在你的設備上,允許我們的改進和定製你的經曆。你可以閱讀更多關於你的餅幹的選擇在我們的隱私政策在這裏。繼續使用這個你同意這些選擇。

Baidu
map